← Product Code [DKZ](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DKZ) · K091588

# UCP HOME DRUG SCREENING TESTS (K091588)

_Ucp Biosciences, Inc. · DKZ · Sep 4, 2009 · Clinical Toxicology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-d%E2%80%94clinical-toxicology-test-systems/DKZ/K091588

## Device Facts

- **Applicant:** Ucp Biosciences, Inc.
- **Product Code:** [DKZ](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DKZ.md)
- **Decision Date:** Sep 4, 2009
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.3100
- **Device Class:** Class 2
- **Review Panel:** Clinical Toxicology

## Indications for Use

The UCP Home Drug Screening Tests are rapid, qualitative, competitive binding immunoassays for the detection the following drugs and their metabolites in human urine: Amphetamine (1000 ng/mL), Barbiturates (300 ng/mL), Benzodiazepines (300 ng/mL), Cocaine (300 ng/mL), Marijuana (50 ng/mL), Methadone (300 ng/mL), Methamphetamine (1000 ng/mL), MDMA (500 ng/mL), Morphine (300 ng/mL), Opiate 2000 (2000 ng/mL), Oxycodone (100 ng/mL), Phencyclidine (25 ng/mL), Tricyclic Antidepressant (1000 ng/mL). The tests contain two formats: 1) Test Card; 2) Test Cup. The test configuration comes with single drug screening test or any combinations of multiple drug screening tests. The test is intended for over-the-counter (OTC) users as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing – the second step in the process, along with the materials for shipping the urine specimen to the laboratory, is provided. The test is also intended for health care professional users. The tests will yield preliminary positive results when the prescription drugs Barbiturates, Benzodiazepines, Oxycodone, Tricyclic Antidepressants are ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Barbiturate, Benzodiazepines, Oxycodone, Tricyclic Antidepressant in urine. The tests provide only preliminary data, which should be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test results, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring drug levels.

## Device Story

UCP Home Drug Screening Test Cards and Cups are lateral flow, competitive binding immunoassays for qualitative drug detection in human urine. Device accepts urine sample directly; no instrumentation required. Principle of operation relies on competitive binding between drug in sample and drug-conjugate on membrane; visual result (colored lines) indicates presence or absence of drug. Used by OTC consumers (parents) or healthcare professionals for preliminary screening. Output is visual qualitative result; preliminary positive requires confirmatory testing via GC/MS or HPLC. Benefits include rapid, accessible initial screening for drug presence, facilitating subsequent clinical or personal decision-making regarding confirmatory testing.

## Clinical Evidence

No clinical trials performed. Evidence consists of a lay user study (n=115 for cards, n=110 for cups) across three locations. Participants (ages 18-75) with varying education levels tested samples spiked with drugs at 0%, 50%, 75%, 125%, 150%, and 300% of cutoff concentrations. Results showed high agreement with expected values (96.9% to 99.1% correct). Post-study questionnaires confirmed 99.1% of participants understood instructions and results.

## Technological Characteristics

Lateral flow immunochromatographic assay; competitive binding principle. Formats: Test Card (up to 10 strips) and Test Cup (up to 5 strips). Urine matrix. Internal procedural control line on each strip. Read time: 5-10 minutes. No instrumentation required.

## Regulatory Identification

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

## Special Controls

*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

## Predicate Devices

- UCP Rapid Drug Screening Tests (k050540)
- UCP Rapid Drug Screening Tricyclic Antidepressants Tests (k061457)
- UCP Multiple Drug Screen Test Cups (k072062)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k091588

B. Purpose for Submission:
This submission is for the addition of an over-the-counter (OTC) claim for already cleared prescription devices: k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, morphine, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclics antidepressants) were both cleared for a strip/ cassette methodology. k072062 supported the cup format for the same device.

C. Measurand:
Amphetamine (d-amphetamine), Barbiturates (secobarbital), Benzodiazepines (oxazepam), Cocaine (benzoylecgonine), Methamphetamine (d-methamphetamine), Methylenedioxymethamphetamine (MDMA), Methadone (methadone), Opiates 2000 (morphine), Morphine 300 (morphine), Oxycodone (oxycodone), Phencyclidine (phencyclidine), and Cannabinoids (THC) (delta-9-THC-COOH) and Tricyclic Antidepressants (nortriptyline).

D. Type of Test:
Qualitative immunochromatographic tests for drugs in urine.

E. Applicant:
UCP Biosciences Inc.

F. Proprietary and Established Names:
UCP Home™ Drug Screening Test Cards
UCP Home™ Drug Screening Test Cup

G. Regulatory Information:

{1}

2

1. Regulation section:

|  Product Code | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  DKZ | II | 21 CFR 862.3100
Amphetamine test system | 91 (Tox)  |
|  DIS | II | 21 CFR 862.3150 Barbiturate test system | 91 (Tox)  |
|  JXM | II | 21 CFR 862.3170
Benzodiazepine test system | 91 (Tox)  |
|  DIO | II | 21 CFR 862.3250 Cocaine and cocaine metabolite test system | 91 (Tox)  |
|  DJC | II | 21 CFR 862.3610
Methamphetamine test system | 91 (Tox)  |
|  DMB | II | 21 CFR 862.3620 Methadone test system | 91 (Tox)  |
|  DJG | II | 21 CFR 862.3650 Opiate test system. | 91 (Tox)  |
|  LCM | II | Unclassified, Enzyme immunoassay, phencyclidine | 91 (Tox)  |
|  LDJ | II | 21 CFR 862.3870 Cannabinoid test system | 91 (Tox)  |
|  LFG | II | 21 CFR 862.3910 Tricyclic antidepressant drugs test system | 91 (Tox)  |

H. Intended Use:

1. Intended use(s):

See indications for use statement below.

2. Indication(s) for use:

The UCP Home Drug Screening Tests are rapid, qualitative, competitive binding immunoassays for the detection the following drugs and their metabolites in human urine:

|  Test | Calibrator | Cut-off  |
| --- | --- | --- |
|  Amphetamine | D-Amphetamine | 1000 ng/mL  |
|  Barbiturates | Secobarbital | 300 ng/mL  |
|  Benzodiazepines | Oxazepam | 300 ng/mL  |
|  Cocaine | Benzoylecgonine | 300 ng/mL  |
|  Marijuana | Delta-9-THC-COOH | 50 ng/mL  |
|  Methadone | Methadone | 300 ng/mL  |
|  Methamphetamine | D-Methamphetamine | 1000 ng/mL  |
|  MDMA | MDMA | 500 ng/mL  |

{2}

3

|  Morphine | Morphine | 300 ng/mL  |
| --- | --- | --- |
|  Opiate 2000 | Morphine | 2000 ng/mL  |
|  Oxycodone | Oxycodone | 100 ng/mL  |
|  Phencyclidine | Phencyclidine | 25 ng/mL  |
|  Tricyclic Antidepressant | Nortriptyline | 1000 ng/mL  |

The tests contain two formats: 1) Test Card; 2) Test Cup. The test configuration comes with single drug screening test or any combinations of multiple drug screening tests. The test is intended for over-the-counter (OTC) users as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing – the second step in the process, along with the materials for shipping the urine specimen to the laboratory, is provided. The test is also intended for health care professional users.

The tests will yield preliminary positive results when the prescription drugs Barbiturates, Benzodiazepines, Oxycodone, Tricyclic Antidepressants are ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Barbiturate, Benzodiazepines, Oxycodone, Tricyclic Antidepressant in urine. The tests provide only preliminary data, which should be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test results, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring drug levels.

3. Special conditions for use statement(s):

For over-the-counter use and health care professional users

4. Special instrument requirements:

None

I. Device Description:

The UCP Home Drug Screening Test Card is capable of measuring 10 of the 13 drugs listed in the intended use at a time. The test cards contain up 10 strips (each strip can hold one drug), five strips on one side of the card and 5 strips on the back side of the card. The UCP Home Drug Screening Test Cup can contain up to five strips that are capable of measuring one drug per strip. Both formats include user instructions, collection cups, transportation bag with absorbent pad, mailing box and identification labels with personal identification number to be used when sending positive urine specimens to the laboratory for confirmation.

J. Substantial Equivalence Information:

{3}

1. Predicate device name(s):

UCP Rapid Drug Screening Tests

UCP Multiple Drug Screen Test Cups

2. Predicate K number(s):

k050540

k072062

3. Comparison with predicate:

This device is the exact same device as the predicate device. This device has the same drugs, cutoffs and same matrix.

This device differs from the predicate in that it is intended to be used over-the-counter and prescription use whereas the predicates are for prescription use only.

K. Standard/Guidance Document Referenced (if applicable):

None referenced.

L. Test Principle:

The UCP Home™ Drug Screening Tests and Cups employ lateral flow immunochromatographic technology based on the principle of competitive binding. Drugs, if present in concentrations below the cutoff level, will not saturate the binding sites of antibody coated particles in the device. The antibody-coated particles will then be captured by immobilized drug-specific conjugate and a colored line will appear in the test line region. The colored line will not form if the sample contains drug in excess of the cutoff level because the drug will saturate all the binding sites of the drug-specific antibody. Each strip in the device contains a procedural control that appears in the control line region indicating that the sample has migrated properly on the test strip.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

This submission is for an OTC claim. Performance characteristics for each of the drugs are found in the following 510(k) numbers: k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclics

4

{4}

antidepressants).

b. Linearity/assay reportable range:

See k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclics antidepressants).

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This device has internal process controls. Each strip in the device contains a procedural control that appears in the control line region indicating that the sample has migrated properly on the test strip. The sponsor informs the user not to interpret the test if a colored line failed to appear in the control region. External controls are not supplied with this device.

The sponsor conducted an incremental time study to support the devices claimed read time of 5 to 10 minutes. Concentrations of amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone and tricyclics antidepressants were prepared at +/-50% and +/-25% of the cutoffs. Twenty determinations were read at each cutoff concentration at 5, 7 and 10 minute intervals. The results supported the sponsors read time of 5 to 10 minutes for the test card and cup.

d. Detection limit:

See k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclic antidepressants).

e. Analytical specificity:

See k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclics antidepressants).

f. Assay cut-off:

See k050540 (amphetamine, cocaine, methamphetamine, MDMA, opiates, phencyclidine, THC, benzodiazepine, methadone, barbiturates oxycodone) and k061457 (tricyclics antidepressants).

2. Comparison studies:

a. Method comparison with predicate device:

{5}

Test Cards:

The sponsor conducted a lay user study for test cards with 115 lay persons in three locations: Texas, Pennsylvania and California. Fifty-eight females and fifty-seven males from ages of 18 to 75 years of age participated in the study. Fifty-eight participants had a high school education or less, fifty-seven participants had completed college courses. None of the participants had experience with a point of care drug testing product.

Test Cups:

The sponsor conducted a lay user study for test cups with 110 lay persons in three locations: Texas, Pennsylvania and California. Fifty-five females and fifty-five males from ages of 18 to 75 years of age participated in the study. Fifty-five participants had a high school education or less, fifty seven participants had completed college courses. None of the participants had experience with a point of care drug testing product.

Quality control samples for test cards and cups were prepared to contain a strong negative (0% of the cutoff), a very weak negative (50% of cutoff), a weak positive (125% of cutoff), a strong positive (150% of cutoff) and a very strong positive (300% of the cutoff) of each drug. The quality control specimens were prepared at concentrations shown below. Pure drug or metabolite was spiked into drug free human urine. All specimens (except TCA samples) were verified by GC/MS. TCA samples were verified by HPLC. In the drug test card study, 4 users tested three samples, 10 users tested five samples, 96 users tested four samples and 5 users tested one two samples. There were 456 total observations. In the drug test cup study, 3 users tested six samples, 96 users tested four samples, 9 users tested five samples, 1 user tested two samples and 1 user tested seven samples. There were 456 observations.

UCP Home Drug Screening Test Card

|  Drug | Cutoff (ng/mL) | Card Results | Drug Concentrations  |   |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |  |  | Negative | 50% of C/O | 75% of C/O | 125% of C/O | 150% of C/O | 300% of C/O | Total % correct  |
|  AMP | 1000 | Positive | 0 | 0 | 1 | 17 | 18 | 17 |   |
|   |   |  Negative | 140 | 17 | 17 | 1 | 0 | 0 |   |
|   |   |  Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |   |  % Agreement | 100 | 100 | 94.4 | 94.4 | 100 | 100 | 99.1  |
|  BAR | 300 | Positive | 0 | 0 | 3 | 16 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 88.9 | 100 | 100 | 97.8  |

{6}

|  BENZO | 300 | Positive | 0 | 0 | 0 | 14 | 18 | 17 |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |  | Negative | 140 | 18 | 18 | 4 | 0 | 0 |   |
|   |  | Total | 140 | 18 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 100 | 77.8 | 100 | 100 | 98.2  |
|  COC | 300 | Positive | 0 | 0 | 2 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 83.3 | 100 | 100 | 97.8  |
|  Methadone | 300 | Positive | 0 | 0 | 1 | 17 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 17 | 1 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 94.7 | 94.4 | 100 | 100 | 99.1  |
|  Methamp | 1000 | Positive | 0 | 0 | 2 | 16 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 88.9 | 100 | 100 | 98.2  |
|  MDMA | 500 | Positive | 0 | 0 | 3 | 14 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 4 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 77.8 | 100 | 100 | 96.9  |
|  Morphine | 300 | Positive | 0 | 0 | 3 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 83.3 | 100 | 100 | 97.4  |
|  Oxycod. | 100 | Positive | 0 | 0 | 2 | 14 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 4 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 77.8 | 100 | 100 | 97.4  |
|  Opiates (Morphine) | 2000 | Positive | 0 | 0 | 3 | 15 | 19 | 18 |   |
|   |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 19 | 18 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 83.3 | 100 | 100 | 97.4  |
|  PCP | 25 | Positive | 0 | 0 | 1 | 16 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 17 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 94.4 | 88.9 | 100 | 100 | 98.7  |
|  TCA | 1000 | Positive | 0 | 0 | 2 | 16 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 88.9 | 100 | 100 | 98.2  |
|  THC | 50 | Positive | 0 | 0 | 2 | 16 | 19 | 18 |   |
|   |  | Negative | 140 | 17 | 16 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 19 | 18 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 88.9 | 100 | 100 | 98.2  |

{7}

UCP Home Drug Screening Test Cups

|  Drug | Cutoff (ng/mL) | Cup Results | Drug Concentrations  |   |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |  |  | Negative | 50% of C/O | 75% of C/O | 125% of C/O | 150% of C/O | 300% of C/O | Total % correct  |
|  AMP | 1000 | Positive | 0 | 0 | 3 | 16 | 18 | 17 |   |
|   |   |  Negative | 140 | 17 | 15 | 2 | 0 | 0 |   |
|   |   |  Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |   |  % Agreement | 100 | 100 | 83.3 | 88.9 | 100 | 100 | 97.8  |
|  BAR | 300 | Positive | 0 | 0 | 4 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 14 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 77.8 | 83.3 | 100 | 100 | 96.9  |
|  BENZO | 300 | Positive | 0 | 0 | 1 | 14 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 17 | 4 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 94.4 | 77.8 | 100 | 100 | 97.8  |
|  COC | 300 | Positive | 0 | 0 | 2 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 83.3 | 100 | 100 | 97.8  |
|  Methadone | 300 | Positive | 0 | 0 | 2 | 16 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 2 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 88.9 | 100 | 100 | 98.2  |
|  Methamp | 1000 | Positive | 0 | 0 | 2 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.8 | 83.3 | 100 | 100 | 97.8  |
|  MDMA | 500 | Positive | 0 | 0 | 3 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.2 | 83.3 | 100 | 100 | 97.4  |
|  Morphine | 300 | Positive | 0 | 0 | 3 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.2 | 83.3 | 100 | 100 | 97.4  |
|  Oxycod. | 100 | Positive | 0 | 0 | 2 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 16 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 88.9 | 83.3 | 100 | 100 | 97.8  |
|  Opiates | 2000 | Positive | 0 | 0 | 3 | 15 | 19 | 18 |   |

{8}

|  (Morphine) |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |  | Total | 140 | 17 | 18 | 18 | 19 | 18 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 83.3 | 100 | 100 | 97.4  |
|  PCP | 25 | Positive | 0 | 0 | 3 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 84.2 | 83.3 | 100 | 100 | 97.4  |
|  TCA | 1000 | Positive | 0 | 0 | 4 | 15 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 14 | 3 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 77.8 | 83.3 | 100 | 100 | 96.9  |
|  THC | 50 | Positive | 0 | 0 | 3 | 14 | 18 | 17 |   |
|   |  | Negative | 140 | 17 | 15 | 4 | 0 | 0 |   |
|   |  | Total | 140 | 17 | 18 | 18 | 18 | 17 |   |
|   |  | % Agreement | 100 | 100 | 83.3 | 77.8 | 100 | 100 | 96.9  |

A Flesh-Kincaid reading analysis was performed on both package inserts (cards and cups) and the score revealed a reading grade level of 7.

Each participant was given a pre and post-study questionnaire. The pre-study questionnaire collected personal information about each participant. The post-study questionnaire was used to determine if the lay users understood the test instruction and the meaning of the results. Consumers were asked questions about the test, control line, prescription drug and food interference and confirmation of results. The results were of the post-questionnaire were acceptable as all of the participants answered the questions correctly (99.1%).

b. Matrix comparison:

Not applicable. The assay is intended for urine samples.

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

{9}

4. Clinical cut-off:
Not applicable.

5. Expected values/Reference range:
Not applicable.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

10

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-d%E2%80%94clinical-toxicology-test-systems/DKZ/K091588](https://fda.innolitics.com/submissions/CH/subpart-d%E2%80%94clinical-toxicology-test-systems/DKZ/K091588)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com